Firm has formed its own sales team and will use NeoGenomics’ services.
Response Genetics is enhancing its sales strategy for its prognostic tests for colon and lung cancers. It has formed an in-house sales team and exclusively signed on NeoGenomics as an authorized national clinical reference laboratory.
ResponseDX: Colon™ and ResponseDX: Lung™ are designed to help with treatment decisions for patients with non-small-cell lung cancer and colorectal cancer. These PCR-based panels include three key genes: ERCC1, TS and EGFR. The tests also include the analysis of K-ras gene mutations, which is a strong predictor of nonresponse and no benefit from the epidermal growth factor receptor inhibitors.
Response Genetics was unavailable to comment on the current uptake of the tests. In March, the firm made ResponseDX: Colon and ResponseDX: Lung available to select medical institutions and practice groups through its CLIA-registered laboratory.
